Heidelberg Pharma AG

    Jurisdiction
    Germany
    LEI
    391200E09XYBYITR1W32
    ISIN
    DE000A11QVV0 (HPHA.DE)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    51 / 100
    Even with peer group:
    51 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    1 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    1 / 7

    Profile

    Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Read full profile

    Fundamentals

    Net revenue
    €5.70M
    Gross margin
    60.7%
    EBIT
    -€25.58M
    EBIT margin
    -448.7%
    Net income
    -€21.54M
    Net margin
    -377.9%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €14.48M +154.0% -€37.17M +72.6%
    €20.57M +42.1% -€33.57M -9.7%
    N/A N/A

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Add to watchlist

    Notifications